Literature DB >> 31658972

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies.

Nieves Carbonell1,2, Gerardo Aguilar2,3, Rafael Ferriols2,4, Rotzel Huerta5,2, José Ferreres5,2, Marisa Calabuig2,6, Mar Juan5,2, Carlos Ezquer2,4, Javier Colomina2,7, M Luisa Blasco5,2.   

Abstract

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; ceftolozane-tazobactam; continuous venovenous hemodiafiltration; medical intensive care unit; molecular adsorbent recirculating system; off-label; pharmacokinetics

Year:  2019        PMID： 31658972      PMCID： PMC7187615          DOI： 10.1128/AAC.01782-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  5 in total

1.  Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Authors:  Joseph L Kuti; Islam M Ghazi; Richard Quintiliani; Eric Shore; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2016-07-08       Impact factor: 5.283

2.  Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.

Authors:  Marc Xipell; Sandra Paredes; Leticia Fresco; Marta Bodro; Francesc Marco; J A Martínez; Alex Soriano
Journal:  J Glob Antimicrob Resist       Date:  2018-01-31       Impact factor: 4.035

3.  Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Authors:  Wesley D Oliver; Emily L Heil; Jeffrey P Gonzales; Shailly Mehrotra; Kathryn Robinett; Paul Saleeb; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy.

Authors:  Heather A Personett; Scott L Larson; Erin N Frazee; Scott L Nyberg; Ziad M El-Zoghby
Journal:  Pharmacotherapy       Date:  2015-08       Impact factor: 4.705

5.  Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration.

Authors:  Gerardo Aguilar; Rafael Ferriols; Sara Martínez-Castro; Carlos Ezquer; Ernesto Pastor; José A Carbonell; Manuel Alós; David Navarro
Journal:  Crit Care       Date:  2019-04-26       Impact factor: 9.097
  5 in total
  3 in total

Review 1.  Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review.

Authors:  Julie Gorham; Fabio Silvio Taccone; Maya Hites
Journal:  Antibiotics (Basel)       Date:  2022-04-20

2.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 3.  Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics.

Authors:  Milo Gatti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2021-06-14       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.